Drug Profile


Alternative Names: 60P 003; Etaquine; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine succinate; UNII-DL5J0B8VSS; WR 238605; WR 238605 succinate

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer 60 Degrees Pharmaceuticals; GlaxoSmithKline; Medicines for Malaria Venture; Walter Reed Army Institute of Research
  • Class Aminoquinolines; Antimalarials; Antiprotozoals; Small molecules
  • Mechanism of Action Apoptosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malaria
  • Discontinued Babesiosis; Pneumocystis pneumonia

Most Recent Events

  • 01 Nov 2016 GlaxoSmithKline completes a phase II trial in Malaria (Combination therapy) in Brazil, Bangladesh, Cambodia, Ethiopia, India, Peru, Philippines and Thailand (NCT01376167)
  • 01 Aug 2016 GlaxoSmithKline completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02751294)
  • 21 Jun 2016 GlaxoSmithKline plans a phase III trial for Malaria (Combination therapy) in Indonesia (NCT02802501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top